Page last updated: 2024-11-04

rofecoxib and Syndrome

rofecoxib has been researched along with Syndrome in 4 studies

Syndrome: A characteristic symptom complex.

Research Excerpts

ExcerptRelevanceReference
"To assess the influence of low dose rofecoxib on inflammatory mediators and prostacyclin synthesis in patients with acute coronary syndromes (ACS) in a short-term follow up."9.11Low dose rofecoxib, inflammation and prostacyclin synthesis in acute coronary syndromes. ( Dobrzycki, S; Kamiński, KA; Kralisz, P; Kuklińska, AM; Modrzejewski, W; Musiał, WJ; Sobkowicz, B; Stec, S; Wojtkowska, I, 2005)
"To assess the influence of low dose rofecoxib on inflammatory mediators and prostacyclin synthesis in patients with acute coronary syndromes (ACS) in a short-term follow up."5.11Low dose rofecoxib, inflammation and prostacyclin synthesis in acute coronary syndromes. ( Dobrzycki, S; Kamiński, KA; Kralisz, P; Kuklińska, AM; Modrzejewski, W; Musiał, WJ; Sobkowicz, B; Stec, S; Wojtkowska, I, 2005)
"Gitelman's syndrome is manifested by hypokalemic alkalosis, hypomagnesemia, hypocalciuria, normotensive hyperreninemia and hyperaldosteronism."1.31Successful treatment by cyclooxyenase-2 inhibitor of refractory hypokalemia in a patient with Gitelman's syndrome. ( Farfel, Z; Gurevitz, O; Mayan, H, 2002)
"Hyperprostaglandin E syndrome/antenatal Bartter syndrome (HPS/aBS) is a congenital salt-losing tubulopathy with an induced expression of cyclooxygenase-2 (COX-2) in the macula densa probably leading to hyperreninemia."1.31Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome. ( Brochhausen, C; Jeck, N; Kömhoff, M; Nüsing, RM; Reinalter, SC; Seyberth, HW; Watzer, B, 2002)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mayan, H1
Gurevitz, O1
Farfel, Z1
Monakier, D1
Mates, M1
Klutstein, MW1
Balkin, JA1
Rudensky, B1
Meerkin, D1
Tzivoni, D1
Kuklińska, AM1
Musiał, WJ1
Kamiński, KA1
Kralisz, P1
Modrzejewski, W1
Sobkowicz, B1
Dobrzycki, S1
Stec, S1
Wojtkowska, I1
Reinalter, SC1
Jeck, N1
Brochhausen, C1
Watzer, B1
Nüsing, RM1
Seyberth, HW1
Kömhoff, M1

Trials

2 trials available for rofecoxib and Syndrome

ArticleYear
Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes.
    Chest, 2004, Volume: 125, Issue:5

    Topics: Acute Disease; Angina, Unstable; C-Reactive Protein; Coronary Disease; Cyclooxygenase Inhibitors; Do

2004
Low dose rofecoxib, inflammation and prostacyclin synthesis in acute coronary syndromes.
    Roczniki Akademii Medycznej w Bialymstoku (1995), 2005, Volume: 50

    Topics: 6-Ketoprostaglandin F1 alpha; Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antichol

2005

Other Studies

2 other studies available for rofecoxib and Syndrome

ArticleYear
Successful treatment by cyclooxyenase-2 inhibitor of refractory hypokalemia in a patient with Gitelman's syndrome.
    Clinical nephrology, 2002, Volume: 58, Issue:1

    Topics: Adult; Alkalosis; Calcium; Cyclooxygenase Inhibitors; Humans; Hyperaldosteronism; Hypokalemia; Lacto

2002
Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome.
    Kidney international, 2002, Volume: 62, Issue:1

    Topics: Adolescent; Adult; Bartter Syndrome; Child; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxyg

2002